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OBJECTIVES: The present study aimed to investigate the trends in changes in pulmonary function and the risk
factors for pulmonary function deterioration in patients with pulmonary tuberculosis after completing treatment.
INTRODUCTION: Patients usually have pulmonary function abnormalities after completing treatment for pulmonary
tuberculosis. The time course for changes in pulmonary function and the risk factors for deterioration have not been
well studied.
METHODS: A total of 115 patients with 162 pulmonary function results were analyzed. We retrieved demographic
and clinical data, radiographic scores, bacteriological data, and pulmonary function data. A generalized additive
model with a locally weighted scatterplot smoothing technique was used to evaluate the trends in changes in
pulmonary function. A generalized estimating equation model was used to determine the risk factors associated
with deterioration of pulmonary function.
RESULTS: The median interval between the end of anti-tuberculosis treatment and the pulmonary function test was
16 months (range: 0 to 112 months). The nadir of pulmonary function occurred approximately 18 months after the
completion of the treatment. The risk factors associated with pulmonary function deterioration included smear-
positive disease, extensive pulmonary involvement prior to anti-tuberculosis treatment, prolonged anti-tuberculosis
treatment, and reduced radiographic improvement after treatment.
CONCLUSIONS: After the completion of anti-tuberculosis TB treatment, several risk factors predicted pulmonary
function deterioration. For patients with significant respiratory symptoms and multiple risk factors, the pulmonary
function test should be followed up to monitor the progression of functional impairment, especially within the first
18 months after the completion of anti-tuberculosis treatment.
KEYWORDS: completion of treatment; disease extent; pulmonary function; pulmonary tuberculosis.
Chung KP, Chen JY, Lee CH, Wu HD, Wang JY, Lee LN. Trends and predictors of changes in pulmonary function after treatment for pulmonary
tuberculosis. Clinics. 2011;66(4):549-556.
Received for publication on October 19, 2010; First review completed on November 17, 2010; Accepted for publication on December 17, 2010
E-mail: jywang@ntu.edu.tw
Tel.: 886-2-2356-2905
INTRODUCTION
Pulmonary tuberculosis (TB) can cause parenchymal destruc-
tion by up-regulation of several proteases and dysregulation of
protease control.
1 The histopathological abnormalities after
treatment for pulmonary TB include fibrosis, bronchiectasis,
and brochial stenosis, all of which can cause pulmonary
function abnormalities.
2–3 Previous studies have evaluated the
changes in pulmonary function before, during and after
pulmonary TB treatment.
4–17 Between 48.7% and 76% of
patients had pulmonary function abnormalities after complet-
ing pulmonary TB treatment.
9–10,13–15,17 Although some studies
have shown obstructive defects as the main abnormality, recent
studies have shown that abnormalities could be obstructive,
restrictive, or mixed defects.
14–15,17 In a study performed on
gold miners in South Africa, forced expiratory volume in the
first second (FEV1) and forced vital capacity (FVC) were found
to be worse six months after tuberculosis treatment and were
stabilized 13 to 18 months after treatment.
16 The impairment in
pulmonary function after completing pulmonary TB treatment
is related to long-term respiratory symptoms, which affect
quality of life.
11–12,18
It is important to identify patients with risk factors for
pulmonary function deterioration after the completion of
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549pulmonary TB treatment. However, little is known about
the trends in the changes in pulmonary function and the risk
factors associated with pulmonary function deterioration.
Therefore, we conducted a study to investigate the trends
and predictors of the changes in pulmonary function in
patients with pulmonary tuberculosis after the completion
of treatment.
METHODS AND MATERIALS
Subjects
From January 2000 to December 2008, 2,789 patients with
culture-confirmed pulmonary TB were identified at the
National Taiwan University Hospital, a tertiary care referral
center with 2,000 beds in northern Taiwan. Among these
patients, 213 (7.6%) underwent pulmonary function tests
after completing pulmonary TB treatment. Ninety-eight
patients were excluded from further analysis due to the
presence of the following conditions before the diagnosis of
pulmonary TB: (1) pulmonary co-morbidities, including
asthma, chronic obstructive airway disease (COPD)
confirmed by spirometry, pneumoconiosis, interstitial
lung disease, history of respiratory failure requiring
mechanical ventilation, lung cancer, and lung resection; (2)
congestive heart failure (New York Heart Association
functional class .2); (3) autoimmune disease; and (4)
human immunodeficiency virus infection.
19 The remaining
115 patients with 162 pulmonary function test results were
analyzed. Tests performed within five years after the end of
anti-tuberculosis treatment were selected to investigate the
predictors of pulmonary function. This study was approved
by the International Review Board of the National Taiwan
University Hospital.
Mycobacteriological studies
Mycobacteriological studies were performed using stan-
dard procedures.
20–22 Briefly, sputum specimens were
decontaminated with NaOH-citrate-N-acetyl-L-cysteine
and then neutralized and centrifuged. The specimen
sediments were inoculated onto Lo ¨wenstein-Jensen (LJ)
slants and into Mycobacterium growth indicator tubes
(MGIT) using a fluorometric BACTEC technique (BACTEC
MGIT 960 system; Becton-Dickinson Diagnostic Instrument
Systems; Sparks, MD). The LJ slants were incubated in a
CO2 incubator for an initial week and in ambient air for
another seven weeks at 35˚C. Growth in MGIT was observed
for at least 42 days. M. tuberculosis was routinely identified
using conventional biochemical methods.
Pulmonary function testing
T h ep u l m o n a r yf u n c t i o nt e s t sw e r ep e r f o r m e du s i n g
MasterScreen, (Jaeger, Germany) or Vmax 6200 (Sensormedics
Figure 1 - Shows a histogram that describes the frequency of pulmonary function tests at each time interval after completion of anti-
tuberculosis treatment.
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550Corp., USA) spirometers in our pulmonary function laboratory,
according to the recommendation by the American Thoracic
Society.
7,23–24 Daily calibration was performed for each machine
before measuring pulmonary function. Patient data, including
age, sex, weight, height, medication history, and smoking
status, were collected via standard questionnaires prior to
pulmonary function testing. Pulmonary function tests were
performed by trained technicians with the patients in sitting
postures. Each patient performed at least three acceptable
forced expiratory maneuvers, which fulfilled the criteria of
repeatability.
24 The reference equations for FEV1,F V C ,a n d
FEV1/FVC were obtained from a previous study of 354 non-
smoking healthy Chinese patients (online supplement 1) and
were used to calculate the predicted values of corresponding
pulmonary function parameters.
25 Normal pulmonary function
should have FEV1 $80%, FVC $80%, and FEV1/FVC $70% of
predicted values. For abnormal pulmonary function, an
obstructive defect wasdefined asFEV1/FVC,70%,a restrictive
defect as an FEV1/FVC ratio $70% and FVC ,80%, and a
mixed defect as FEV1/FVC ,70% and FVC ,80% of predicted
values.
Data collection
From patients’ medical records, we retrieved demo-
graphic data, smoking history, underlying co-morbidities,
radiographic findings, laboratory results, pulmonary TB
treatment courses, and results of pulmonary function tests.
The standard anti-tuberculosis regimen consisted of oral
isoniazid, rifampicin, and ethambutol, plus pyrazinamide
daily during the first two months and isoniazid plus
rifampicin daily during the following four months.
According to previous studies, non-tuberculosis myco-
bacteria (NTM) are present in the respiratory tracts of 7.1%
to 7.3% of patients with pulmonary tuberculosis.
26–27 It was
unknown whether these NTM isolates would cause pul-
monary function deterioration. Therefore, we recorded the
frequency of NTM isolates (0, 1 or $2) from sputum
samples collected after beginning anti-tuberculosis treat-
ment and before pulmonary function testing.
Chest radiographs that were obtained before and after
anti-tuberculosis treatment were reviewed. Radiographic
scores (RS) of chest radiographs
9 that were taken before and
after anti-tuberculosis treatment were recorded (in accor-
dance with a previous study) to define the extent of the
disease. Briefly, each lung was divided into three areas, and
each area was rated on a four-point scale (0 to 3) for the
extent of infiltration. The sum of the points from all six areas
constituted the RS. A greater extent of infiltration resulted in
a larger RS.
Statistical analysis
Continuous variables were reported as means (standard
deviation) and categorical variables as numbers (percen-
tage). Changes in pulmonary function over time after the
completion of anti-tuberculosis treatment have been shown
to be biphasic (non-linear).
16 Therefore, we first established
three generalized additive models for FEV1, FVC, and
FEV1/FVC, with the Gaussian distribution selected.
7 In
Table 1 - Clinical data and pulmonary function results.
Characteristic Entire group (N=106) Patients with NTM isolates (N=28)
Clinical data
Age (years) 59.3 [21.2] 71.1 [14.8]
Male 80 (75.5%) 23 (82.1%)
History of smoking 51 (48.1%) 15 (53.6%)
Co-morbidity
Malignancy* 11 (10.4%) 3 (10.7%)
Diabetes mellitus 10 (9.4%) 5 (17.9%)
Smear-positive 43 (40.6%) 12 (42.9%)
Modification of anti-tuberculosis regimen 20 (18.9%) 5 (17.9%)
Treatment duration (months) 9.2 [4.3] 8.4 [2.9]
Radiographic score before treatment 6.5 [4.6] 7.0 [3.9]
Radiographic score after treatment 3.4 [3.3] 4.2 [3.9]
Non-tuberculosis mycobacterium isolate
{
0 78 (73.6%)
1 16 (15.1%)
$ 2 12 (11.3%)
Pulmonary function results
{
FEV1 (L) 1.90 [0.79] 1.77 [0.78]
FEV1/predicted FEV1 (%) 77.25 [26.44] 86.37 [31.88]
FVC (L) 2.71 [0.89] 2.41 [0.97]
FVC/predicted FVC (%) 87.94 [20.75] 88.08 [26.92]
FEV1/FVC (%) 70.35 [15.40] 74.67 [14.77]
Interpretation
Normal 46 (32.9%) 13 (33.3%)
Obstructive 68 (48.6%) 16 (41.0%)
Restrictive 13 (9.3%) 4 (10.3%)
Mixed 13 (9.3%) 6 (15.4%)
The data are presented as number (percentage) or mean [standard deviation].
*The malignancies were head and neck cancer in 3, gastrointestinal cancer in 3, breast cancer in 2, and 1 each for hepatocellular carcinoma, prostate
cancer and bladder cancer. All of these patients had no clinical evidence of pulmonary metastases before the pulmonary function test.
{Including 8 Mycobacterium avium complex, 17 rapidly growing mycobacteria, 2 Mycobacterium gordonae, and 1 Mycobacterium scrofulaceum.
{For the entire group, 140 pulmonary function tests were recorded within 5 years after the end of anti-tuberculosis treatment, whereas 39 pulmonary
function tests were recorded for patients with NTM isolates.
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552addition to time after the completion of pulmonary TB
treatment, we included 3 other covariates into these models:
age, body weight, and height. Locally weighted scatterplot
smoothing (LOESS) was selected as the smoothing techni-
que for the smooth functions of the four covariates. From
the partial prediction curves of the smooth functions of time
after the completion of pulmonary TB treatment, we
determined the time point at which the worst pulmonary
function occurred.
Some subjects who were enrolled in this study performed
repeated pulmonary function tests over time. The pulmon-
ary function test results were not independent of each other,
and a generalized linear model could not be applied for
analysis. Therefore, we performed statistical analyses using
generalized estimating equation (GEE) models with a
stepwise variable selection procedure to identify the
predictors of pulmonary function (FEV1 and FVC) and the
predictors of obstructive defect development within 5 years
after completion of pulmonary TB treatment. The time
interval (DT) between the date of each pulmonary function
test and the timing of the worst pulmonary function
(obtained by LOESS smoothing models) was included in
the analysis. Other parameters with the potential to
influence pulmonary function after completion of pulmon-
ary TB treatment were also included in the analysis; these
parameters were demographic data, smoking history,
underlying co-morbidities, radiographic findings, labora-
tory results, and pulmonary tuberculosis treatment courses.
A two-sided p value ,0.05 was considered to be significant.
All analyses were performed using SAS software (version
9.1.3, SAS Institute Inc., Cary, NC, U.S.A.).
RESULTS
Patients and pulmonary function
A total of 115 patients underwent 162 pulmonary function
tests after they completed pulmonary TB treatment within
the study period. Twenty-eight patients had more than one
pulmonary function test result, and the time between
repeated pulmonary function tests was at least six months
(Figure 1). The median interval between the completion of
pulmonary tuberculosis treatment and a pulmonary func-
tion test was 16 months (range: 0 to 112 months). Among
these 115 patients, 106 (92.2%) underwent 140 (86% of all
pulmonary function tests) pulmonary function tests within 5
years. Table 1 summarizes the baseline clinical character-
istics of these 106 patients and the results of the 140
pulmonary function tests. The mean age at the first
pulmonary function test was 59.3 years (range: 19 to 90).
Ninety-four (67.1%) pulmonary function tests were abnor-
mal, with obstructive defects being the most common
problem (68 tests, 48.6%). Twenty-eight patients (26.4%)
had at least one concurrent NTM isolate; these patients
contributed 39 pulmonary function test results (Table 1).
The mean age at which the patients underwent their first
pulmonary function test was older in those patients with
NTM isolates (p,0.001 by Student’s t-test, compared to
those without NTM isolates). Otherwise, they had no
significantly different characteristics compared to those
patients without NTM isolates.
From partial prediction curves, we observed trends of
biphasic changes in FEV1, FVC, and the FEV1/FVC ratio with
time after completion of pulmonary tuberculosis treatment
(Figure2A–C). Deterioration of pulmonary functionoccurred
initially. The nadirsofthethreesmoothingcurves occurredat
18 months.
Predictors of pulmonary function after completion
of anti-tuberculosis treatment
The predictors of FEV1 within 60 months after completion
of anti-tuberculosis treatment are shown in Table 2 (for
statistical details, please refer to online supplement 2). The
time variable (DT), defined as the absolute time interval
between the date of the pulmonary function test and the
timing of worst FEV1 (i.e., 18 months), was significantly
correlated with FEV1. Patients who had smear-positive
disease, longer treatment duration, higher RS before
treatment, or less RS improvement after treatment had
worse FEV1 after completion of anti-tuberculosis treatment.
From the end of the anti-tuberculosis treatment to the nadir
of FEV1, the estimated monthly reduction in FEV1 was
18.83 mL (0.017 L/month * 1 month + 0.022 L/year * 1
month/12=0.01883 L) after adjusting for the other para-
meters.
The predictors of FVC within 60 months after completion
of anti-tuberculosis treatment are listed in Table 3. Patients
had worse FVC after completion of anti-tuberculosis
treatment if they had longer treatment duration, a change
in regimen during treatment, higher RS before treatment, or
less RS improvement after treatment.
We also investigated the risk factors of obstructive defects
(FEV1/FVC ratio ,70) after completion of treatment for
pulmonary TB (Table 4). Patients with smear-positive
disease had a higher risk of obstructive defects after
completing anti-tuberculosis treatment (odds ratio 2.546,
p=0.045).
DISCUSSION
Our results showed that after completing pulmonary TB
treatment, patients experienced gradual declines in pul-
monary function until approximately 18 months. The risk
factors for pulmonary function deterioration in association
with TB included smear-positive disease, extensive pul-
monary involvement with poor radiographic improvement
after treatment, prolonged duration of treatment, and
change in regimen.
Several co-morbidities could affect pulmonary function
test results, including chronic lung diseases, severe con-
gestive heart failure, autoimmune diseases, and HIV
infection. Autoimmune diseases could have pulmonary
involvement, possibly leading to significant changes in
pulmonary function.
28 In addition, patients with HIV
infection have a high risk of contracting respiratory diseases
such as Pneumocystis jirovecii infection and recurrent
bacterial pneumonia.
29 Therefore, in our study, we excluded
Figure 2 - Shows partial prediction curves that describe how the time after completing anti-tuberculosis treatment affected changes in
pulmonary function, including FEV1 (2A), FVC (2B), and FEV1/FVC (2C). The y axis refers to the changes in FEV1 (L) (2A), FVC (L) (2B), and
FEV1/FVC (%) (2C) at different time points after completing anti-tuberculosis treatment (time 0: end of anti-tuberculosis treatment).
The shaded areas denote 95% confidence intervals. The maximal reduction in pulmonary function occurred approximately 18 months
after completion of anti-tuberculosis treatment.
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553patients with these co-morbidities to give a more accurate
description of the changes in pulmonary function and
trends after completion of pulmonary TB treatment.
The time course for changes in pulmonary function after
completing anti-tuberculosis treatment has never been well-
studied. One previous study showed that the annual
decrease in FEV1 was 35.3 mL in patients with obstructive
defects within 15 years after the end of anti-tuberculosis
treatment.
30 However, the anti-tuberculosis treatment in this
study was less effective than the modern four-drug
combination regimen, and exposure to other noxious
environmental factors may have contributed to changes in
pulmonary function during long follow-up time periods. In
a study performed in Cape Town, South Africa by Hnizdo et
al., the pulmonary function of coal miners with pulmonary
TB reached a nadir at approximately 6 months after
completing anti-tuberculosis treatment (with a monthly
FEV1 reduction of 56.8 mL) and stabilized approximately 7
to 12 months later.
16 Our results confirmed the biphasic
change in pulmonary function over time after the end of
anti-tuberculosis treatment, with a monthly FEV1 reduction
of 18.83 mL within the first 18 months. The greater declines
in pulmonary function that were noted in the coal miners
with TB were probably due to the concomitant presence of
pneumoconiosis. In addition, without adjusting for smoking
history or disease extent in the analysis, it is difficult to
determine the contribution of each factor to the abnormal-
ities in pulmonary function.
Smear-positive disease, which suggests either a high
mycobacterial load or endobronchial involvement, has been
shown to be an important predictor of pulmonary function
deterioration and obstructive defects after the completion of
pulmonary TB treatment.
31 In accordance with previous
studies, we found that disease extent was a predictor of
pulmonary function deterioration after the completion of
pulmonary TB treatment.
10,12–13 However, the previous
studies did not consider the timing of the pulmonary
function test. Smoking, which is the most important risk
factor for COPD, increases the risk of active pulmonary
tuberculosis.
32–34 The impact of smoking on pulmonary
function abnormalities after pulmonary TB infection is
unknown, and previous studies have shown inconsistent
results.
9–10,15,17 In our study, smoking history was not a
significant predictor of pulmonary function deterioration.
The reason for this finding might be that most subjects with
a history of smoking in our study had quit smoking before
or immediately after their diagnosis with pulmonary TB,
and subjects with COPD, as confirmed by spirometry, were
excluded. It might also be the case that short-term changes
in pulmonary function are mainly caused by post-tubercu-
losis pulmonary inflammation, which masks pulmonary
function deterioration due to smoking.
It is not uncommon for patients with pulmonary TB to
have NTM isolation from respiratory specimens.
26–27 The
clinical significance of NTM isolation, especially with
respect to pulmonary function, is unclear in pulmonary
tuberculosis patients; it might be the result of colonization,
specimen contamination or true infection.
35 Patients with
multiple NTM isolates were more likely to be symptomatic
and had longer treatment times for pulmonary TB.
Cavitations were more frequently visualized by chest
radiographs in patients with NTM isolates.
26 Further study
Table 2 - Predictors of FEV1 within 60 months after completion of treatment for pulmonary tuberculosis.
Parameter Estimate (bi) Standard error 95% confidence interval p value
Male 0.607 0.212 0.192–1.024 0.004
Height (cm) 0.019 0.009 0.001–0.036 0.036
Age (years) 20.022 0.004 20.030– 20.013 ,0.001
Smear-positive disease 20.334 0.110 20.549– 20.120 0.002
Treatment duration (months) 20.023 0.010 20.043– 20.003 0.023
RS before treatment 20.074 0.019 20.112– 20.037 ,0.001
DRS after treatment* 20.055 0.025 20.104– 20.006 0.027
DT (months) 0.017 0.006 0.006–0.028 0.003
One NTM isolate
{ 0.361 0.148 0.071–0.651 0.015
Definitions of abbreviations: RS: radiographic score; DT: the absolute of the time interval between the date of the pulmonary function test to the time of
the pulmonary function nadir (i.e., 18 months); NTM: non-tuberculosis mycobacterium.
*DRS = (RS after treatment) – (RS before treatment). Patients with more radiographic improvement had more negative DRS values.
{Only one NTM isolate was obtained from sputum samples during the time between the diagnosis of pulmonary tuberculosis and the pulmonary function
test.
Table 3 - Predictors of FVC within 60 months after completion of treatment for pulmonary tuberculosis.
Parameter Estimate (bi) Standard error 95% confidence interval p value
Male 0.613 0.134 0.351–0.876 ,0.001
Weight (kg) 0.020 0.006 0.008–0.031 0.001
Diabetes mellitus 20.453 0.186 20.819– 20.088 0.015
Malignancy 20.588 0.185 20.951– 20.226 0.002
Treatment duration (months) 20.035 0.012 20.058– 20.012 0.003
Change in regimen 20.039 0.118 20.571– 20.107 0.004
RS before treatment 20.112 0.027 20.164– 20.059 ,0.001
DRS after treatment* 20.102 0.029 20.159– 20.045 0.001
Definition of abbreviation: RS: radiographic score.
*DRS = (RS after treatment)–(RS before treatment). Patients with more radiographic improvement had more negative DRS values.
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554is needed to clarify the clinical significance of NTM
colonization in changes in pulmonary function after
completion of anti-tuberculosis treatment.
There are some limitations of our study. First, the study
was limited by retrospective data and a relatively small
sample size. Without longitudinal follow-up data, we could
miss individual characteristics that might have significant
impacts on pulmonary function. Second, selection bias
might exist because our study population was treated in a
tertiary medical center. Nevertheless, we believe that this is
a minor concern because more than 90% of the patients with
pulmonary TB were ambulatory and sought primary care in
the outpatient department. Third, only 7.3% of our patients
underwent pulmonary function tests after completing anti-
tuberculosis treatment. Patients who received pulmonary
function tests could have had more prominent respiratory
symptoms and worse pulmonary function compared to
patients who did not undergo such tests. Nevertheless, our
results showed a prominent loss of pulmonary function
after pulmonary TB infection. Pulmonary function follow-
up analysis is recommended in patients with pre-existing
lung disease who are at risk of pulmonary decompensation
after pulmonary tuberculosis.
CONCLUSIONS
In conclusion, after completion of pulmonary TB treat-
ment, the risk factors for pulmonary function deterioration
include smear-positive disease, extensive disease before
treatment, prolonged treatment duration, and less radio-
graphic improvement after treatment. For patients with
significant respiratory symptoms and multiple risk factors,
the pulmonary function test should be followed up to
monitor the progression of functional impairment and
responses to treatment, especially within the first 18 months
after completing anti-tuberculosis treatment.
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